Biosig Technologies Free Cash Flow 2012-2024 | BSGM
Biosig Technologies free cash flow from 2012 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Biosig Technologies Annual Free Cash Flow | |
|---|---|
| 2024 | -4.76 |
| 2023 | -17.50 |
| 2022 | -21.87 |
| 2021 | -26.94 |
| 2020 | -26.69 |
| 2019 | -15.66 |
| 2018 | -10.29 |
| 2017 | -7.48 |
| 2016 | -5.12 |
| 2015 | -4.54 |
| 2014 | -2.00 |
| 2013 | -1.77 |
| 2012 | -1.54 |
| 2011 | -0.87 |
| Biosig Technologies Quarterly Free Cash Flow | |
|---|---|
| 2024-12-31 | -4.76 |
| 2024-09-30 | -4.28 |
| 2024-06-30 | -2.80 |
| 2024-03-31 | -1.31 |
| 2023-12-31 | -17.50 |
| 2023-09-30 | -14.55 |
| 2023-06-30 | -10.67 |
| 2023-03-31 | -5.69 |
| 2022-12-31 | -21.87 |
| 2022-09-30 | -17.70 |
| 2022-06-30 | -12.70 |
| 2022-03-31 | -6.00 |
| 2021-12-31 | -26.94 |
| 2021-09-30 | -21.07 |
| 2021-06-30 | -14.09 |
| 2021-03-31 | -7.12 |
| 2020-12-31 | -26.69 |
| 2020-09-30 | -20.56 |
| 2020-06-30 | -14.25 |
| 2020-03-31 | -5.96 |
| 2019-12-31 | -15.66 |
| 2019-09-30 | -11.67 |
| 2019-06-30 | -7.69 |
| 2019-03-31 | -3.54 |
| 2018-12-31 | -10.29 |
| 2018-09-30 | -7.31 |
| 2018-06-30 | -4.81 |
| 2018-03-31 | -2.39 |
| 2017-12-31 | -7.48 |
| 2017-09-30 | -5.22 |
| 2017-06-30 | -3.46 |
| 2017-03-31 | -1.61 |
| 2016-12-31 | -5.12 |
| 2016-09-30 | -3.86 |
| 2016-06-30 | -2.77 |
| 2016-03-31 | -1.17 |
| 2015-12-31 | -4.54 |
| 2015-09-30 | -3.44 |
| 2015-06-30 | -2.58 |
| 2015-03-31 | -1.22 |
| 2014-12-31 | -2.00 |
| 2014-09-30 | -1.54 |
| 2014-06-30 | -0.96 |
| 2014-03-31 | -0.51 |
| 2013-12-31 | |
| 2013-09-30 | -1.68 |
| 2013-06-30 | -1.16 |
| 2012-12-31 | |
| 2011-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.030B | $0.000B |
| BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company's first product, PURE EP (tm) System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. | |||